Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Aiding in identifying individuals with an adaptive immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), indicating recent or prior infection
This test provides qualitative detection of serum antibodies against the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), the causative agent of coronavirus disease 2019 (COVID-19).
This test will not yield a positive result following vaccination against SARS-CoV-2.
This test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
Fact sheets for this emergency use authorization (EUA) assay can be found at the following links:
For healthcare providers: www.fda.gov/media/137603/download
For patients: www.fda.gov/media/137604/download
Chemiluminescence Immunoassay (CIA)